Drug discovery and development – Page 27
-
FeatureThe rising tide of 'legal highs'
Andy Extance investigates the chemistry that has helped recreational drugs evade the law, and its consequences
-
OpinionMake room for randomness in drug development
Setting free the dark horses sometimes beats the most rational planning
-
WebinarCurrent topics in bioconjugation
Insights into making bioconjugates using optimal reagents and the latest techniques to create highly active and stable complexes
-
FeatureEnvironmentally benign by design
The challenge of designing drugs with biodegradability in mind
-
ResearchSingle-cell imaging spots resistant infections in less than half an hour
Microfluidic device allows speedy susceptibility testing so the right antibiotic can be given
-
ResearchStructural sleuthing salvages superbug slayer
Combining ‘assembly line’ synthesis, spectroscopy and computational predictions solves stereochemistry riddle
-
ResearchPlotting a course to new antibiotics
Mapping out the chemical space of peptide antibiotics offers an efficient way to find new compounds
-
BusinessAstraZeneca shares tumble after antibody failure
Imfinzi and tremelimumab checkpoint inhibitor pairing fails to beat chemotherapy in lung cancer
-
BusinessNovartis coasts towards first CAR-T approval
Unanimous recommendation for CTL019 ahead of October decision builds confidence in T-cell genetic reprogramming
-
Opinion(+)-Pleuromutilin
Total synthesis is sometimes the only way to explore the chemical space around a natural product
-
ResearchSimplified structure eases antibiotic synthesis
New analogues of the potent antibiotic teixobactin could be instrumental in the fight against multi-drug resistant pathogens
-
OpinionMaking enough of a difference
What if the needle in the drug development haystack ends up being too small to be useful?
-
BusinessFDA approves first sickle cell drug in almost two decades
Glutamine-based drug is the first approved for children over 5
-
BusinessAmplifying intelligent drug design
This year’s Chemistry World Entrepreneur of the year is Andrew Hopkins of start-up Exscientia and the University of Dundee, UK
-
NewsEuropean ‘One Health’ plan aims to curb antimicrobial resistance
Action plan treats human and animal health as interconnected
-
ArticleSygnature Discovery
Sygnature Discovery is part of an innovative partnership to bolster the life science sector in Nottingham
-
OpinionUnpicking a clinical trial death
A new study shows up off-target effects of a drug that proved deadly, and highlights the pitfalls of drug discovery
-
FeatureAccess to drugs: a failure of pharma?
Many people around the world are either unable to afford the drugs they need, or their conditions have not been addressed by pharma R&D. Sarah Houlton investigates
-
ResearchModified antibiotic beats superbug resistance
Adding functional groups to vancomycin gives it extra modes of attack against resistant bacteria
-
OpinionDrug pricing must be more transparent
Pricing is a complex issue - how can we make it clearer?